Blood Reviews
Volume 20, Issue 4 , Pages 201-212 , July 2006

Antiphospholipid syndrome: An evolving story

  • Beverley Robertson

      Affiliations

    • Department of Haematology, Aberdeen Royal Infirmary, ABERDEEN, AB25 2ZN, Scotland, U.K.
    • Corresponding Author InformationCorresponding author. Tel.: +01224 681818x53789(pager 3190); fax: +01224 550714.
    • ,
  • Mike Greaves

      Affiliations

    • Department of Medicine and Therapeutics, Polwarth Building, University of Aberdeen, ABERDEEN, AB25 2ZD, Scotland, U.K.
    • Tel.: +01224 553016.

References 

  1. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop.[review] [22 refs]. Arthritis & Rheumatism. 1999 Jul;42(7):1309–11.
  2. Petri M. Epidemiology of the antiphospholipid antibody syndrome. Journal of Autoimmunity. 2000;15(2):145–151[review] [63 refs]
  3. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins lupus cohort. Thromb Res. 2004;114(5-6):593–595
  4. Topping J, Quenby S, Farquharson R, Malia R, Greaves M. Marked variation in antiphospholipid antibodies during pregnancy: Relationships to pregnancy outcome. Human Reproduction. 1999;14(1):224–228
  5. Pattison NS, Chamley LW, McKay EJ, Liggins GC, Butler WS. Antiphospholipid antibodies in pregnancy: Prevalence and clinical associations. British Journal of Obstetrics & Gynaecology. 1993;100(10):909–913
  6. MacLean MA, Cumming GP, McCall F, Walker ID, Walker JJ. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. British Journal of Obstetrics & Gynaecology. 1994;101(2):103–106
  7. Lynch A, Byers T, Emlen W, Rynes D, Shetterly SM, Hamman RF. Association of antibodies to beta2-glycoprotein 1 with pregnancy loss and pregnancy-induced hypertension: A prospective study in low-risk pregnancy. Obstetrics & Gynecology. 1999;93(2):193–198
  8. Simmelink MJ, Horbach DA, Derksen RH, Meijers JC, Bevers EM, Willems GM, et al. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br J Haematol. 2001;113(3):621–629
  9. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood. 2004;104(12):3598–3602
  10. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA. 1991;88(8):3069–3073
  11. Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis. American Journal of Obstetrics & Gynecology. 1993;168(1 Pt 1):206–210
  12. Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thrombosis & Haemostasis. 1998;79(2):276–281
  13. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol. 1990;76(1):101–107
  14. Atsumi T, Khamashta MA, Amengual O, Donohoe S, Mackie I, Ichikawa K, et al. Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): A possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. Clinical & Experimental Immunology. 1998;112(2):325–333
  15. Atsumi T, Khamashta MA, Andujar C, Leandro MJ, Amengual O, Ames PR, et al. Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. J Rheumatol. 1998;25(1):69–73
  16. Ford I, Urbaniak S, Greaves M. IgG from patients with antiphospholipid syndrome binds to platelets without induction of platelet activation. Br J Haematol. 1998;102(3):841–849
  17. Hill MB, Phipps JL, Malia RG, Greaves M, Hughes P. Characterization and specificity of anti-endothelial cell membrane antibodies and their relationship to thrombosis in primary antiphospholipid syndrome (APS). Clinical & Experimental Immunology. 1995;102(2):368–372
  18. Hill MB, Phipps JL, Hughes P, Greaves M. Anti-endothelial cell antibodies in primary antiphospholipid syndrome and SLE: Patterns of reactivity with membrane antigens on microvascular and umbilical venous cell membranes. Br J Haematol. 1998;103(2):416–421
  19. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation. 1999;99(15):1997–2002
  20. Branch DW, Dudley DJ, Mitchell MD, Creighton KA, Abbott TM, Hammond EH, et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: A model for autoimmune fetal loss. American Journal of Obstetrics & Gynecology. 1990;163(1 Pt 1):210–216
  21. Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J, et al. Pregnancy loss in the antiphospholipid-antibody syndrome–a possible thrombogenic mechanism. N Engl J Med. 1997;337(3):154–160
  22. Rand JH, Wu XX, Andree HA, Ross JB, Rusinova E, Gascon-Lema MG, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: A “lupus procoagulant phenomenon. Blood. 1998;92(5):1652–1660
  23. Bevers EM, Janssen MP, Willems GM, Zwaal RF. No evidence for enhanced thrombin formation through displacement of annexin V by antiphospholipid antibodies. Thrombosis & Haemostasis. 2000;83(5):792–794
  24. Chamley LW, Duncalf AM, Mitchell MD, Johnson PM. Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet. 1998;352(9133):1037–1038
  25. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10(11):1222–1226
  26. Bengtsson AA, Sturfelt G, Gullstrand B, Truedsson L. Induction of apoptosis in monocytes and lymphocytes by serum from patients with systemic lupus erythematosus - an additional mechanism to increased autoantigen load?. Clinical & Experimental Immunology. 2004;135(3):535–543
  27. Kuwana M, Matsuura E, Kobayashi K, Okazaki Y, Kaburaki J, Ikeda Y, et al. Binding of beta 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood. 2005;105(4):1552–1557
  28. de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. Journal of Thrombosis & Haemostasis. 2005;3(9):1993–1997
  29. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome. clinical and laboratory features of 50 patients. [review] [59 refs]. Medicine. 1998;77(3):195–207
  30. Greaves M, Cohen H, MacHin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. British Journal of Haematology. 2000;109(4):704–715
  31. Jennings I, Greaves M, Mackie IJ, Kitchen S, Woods TA, Preston FE, et al. Lupus anticoagulant testing: Improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. Br J Haematol. 2002;119(2):364–369
  32. Reber G, Arvieux J, Comby E, Degenne D, de Moerloose P, Sanmarco M, et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. the working group on methodologies in haemostasis from the GEHT (groupe d’etudes sur l’hemostase et la thrombose). Thrombosis & Haemostasis. 1995;73(3):444–452
  33. Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: A cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol. 2002;118(4):548–557
  34. Reber G, Schousboe I, Tincani A, Sanmarco M, Kveder T, de Moerloose P, et al. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the european forum on antiphospholipid antibodies standardization group. Thrombosis & Haemostasis. 2002;88(1):66–73
  35. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. [review] [58 refs]. Blood. 2003;101(5):1827–1832
  36. Finazzi G, Brancaccio V, Moia M, Ciaverella N, Mazzucconi MG, Schinco PC, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the italian registry. Am J Med. 1996;100(5):530–536
  37. Statkute L, Traynor A, Oyama Y, Yaung K, Verda L, Krosnjar N, et al. Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood. 2005;106(8):2700–2709
  38. Yoon KH. Sufficient evidence to consider hydroxychloroquine as an adjunct therapy in antiphospholipid antibody (hughes’) syndome. J Rheumatol. 2002;29(7):1574–1575
  39. Merrill JT. Rituximab in antiphospholipid syndrome. Curr Rheumatol Rep. 2003;5:381–382
  40. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332(15):993–997
  41. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;18;349(12):1133–1138
  42. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). Journal of Thrombosis & Haemostasis. 2005;3(5):848–853
  43. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. duration of anticoagulation study group. Am J Med. 1998;104(4):332–338
  44. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291(5):576–584
  45. “SPIRIT Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. the stroke prevention in reversible ischemia trial (SPIRIT) study group. Ann Neurol. 1997 Dec;42(6):857–65.
  46. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345(20):1444–1451
  47. Khamashta MA, Hunt BJ. Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? no. Journal of Thrombosis & Haemostasis. 2005;3(5):844–845
  48. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314(7076):253–257
  49. Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: Prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertility & Sterility. 2005;83(3):684–690
  50. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: A randomized, controlled trial of treatment. Obstetrics & Gynecology. 2002;100(3):408–413
  51. Silver RK, MacGregor SN, Sholl JS, Hobart JM, Neerhof MG, Ragin A. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. American Journal of Obstetrics & Gynecology. 1993;169(6):1411–1417
  52. Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. American Journal of Obstetrics & Gynecology. 2000;183(4):1008–1012
  53. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low-dose heparin treatment. American Journal of Obstetrics & Gynecology. 1992;166(5):1318–1323
  54. Laskin CA, Bombardier C, Hannah ME, Mandel FP, Ritchie JW, Farewell V, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med. 1997;;337(3):148–153
  55. Branch DW, Peaceman AM, Druzin M, Silver RK, El-Sayed Y, Silver RM, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. the pregnancy loss study group. American Journal of Obstetrics & Gynecology. 2000;182(1 Pt 1):122–127
  56. Triolo G, Ferrante A, Ciccia F, Accardo-Palumbo A, Perino A, Castelli A, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis & Rheumatism. 2003;48(3):728–731
  57. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. [review] [103 refs]. Cochrane Database of Systematic Reviews. 2005;(2):002859
  58. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med. 1997;127(3):177–185
  59. Tripodi A, Chantarangkul V, Clerici M, Negri B, Galli M, Mannucci PM. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. results of a collaborative study involving nine commercial thromboplastins. Br J Haematol. 2001;115(3):672–678
  60. Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, et al. Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines. [review] [9 refs]. Lupus. 2003;12(7):530–534
  61. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Annals of Internal Medicine. 1992;117(12):997–1002
  62. Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995;91(1):23–27
  63. Vaarala O, Puurunen M, Manttari M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thrombosis & Haemostasis. 1996;75(3):456–459
  64. Ahmed E, Stegmayr B, Trifunovic J, Weinehall L, Hallmans G, Lefvert AK. Anticardiolipin antibodies are not an independent risk factor for stroke: An incident case-referent study nested within the MONICA and vasterbotten cohort project. Stroke. 2000;31(6):1289–1293
  65. Vila P, Hernandez MC, Lopez-Fernandez MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thrombosis & Haemostasis. 1994;72(2):209–213
  66. Runchey SS, Folsom AR, Tsai MY, Cushman M, McGovern PD. Anticardiolipin antibodies as a risk. Br J Haematol. 2002;119(4):1005–1010
  67. Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins JC. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. American Journal of Obstetrics & Gynecology. 1989;161(2):369–373
  68. Lynch A, Marlar R, Murphy J, Davila G, Santos M, Rutledge J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med. 1994;120(6):470–475
  69. Katano K, Aoki A, Sasa H, Ogasawara M, Matsuura E, Yagami Y. Beta 2-glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Human Reproduction. 1996;11(3):509–512

PII: S0268-960X(05)00069-X

doi: 10.1016/j.blre.2005.12.001

Blood Reviews
Volume 20, Issue 4 , Pages 201-212 , July 2006

Article Tools